Targeting the protein-protein interaction between IRS1 and mutant p110α for cancer therapy.
about
Oncogenic PIK3CA mutations reprogram glutamine metabolism in colorectal cancer.RPPA-based protein profiling reveals eIF4G overexpression and 4E-BP1 serine 65 phosphorylation as molecular events that correspond with a pro-survival phenotype in chronic lymphocytic leukemia.Regulation of paxillin-p130-PI3K-AKT signaling axis by Src and PTPRT impacts colon tumorigenesis.
P2860
Targeting the protein-protein interaction between IRS1 and mutant p110α for cancer therapy.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Targeting the protein-protein ...... tant p110α for cancer therapy.
@en
type
label
Targeting the protein-protein ...... tant p110α for cancer therapy.
@en
prefLabel
Targeting the protein-protein ...... tant p110α for cancer therapy.
@en
P2860
P356
P1476
Targeting the protein-protein ...... tant p110α for cancer therapy.
@en
P2093
Shuliang Zhao
P2860
P304
P356
10.1177/0192623313506794
P407
P50
P577
2013-10-31T00:00:00Z